Figure S1


A
α-SMA
AR
Ki67
F4/80
Ly6G
CD3
Control
2 month
6 month
12 month
ERGpce-
ERGpce-
ERGpce-
ERGpce+
ERGpce-
ERGpce+


B
F4/80
Ly6G
Ki67
α-SMA
Cells (% pos)
Pixels (% pos)
6 mo.
End-stage or 12 mo.
Control
ERGpce-
ERGpce+


C
Ptenpce-/-Trp53pce-/-TMPRSS2-ERGpce+
Vehicle
Lupron


D
Ptenpce-/-Trp53pce-/-
Ptenpce-/-Trp53pce-/-ERGpce+
n=5
n=4
n=3
n=3
***
Percent of mice
Vehicle
Lupron
>2-fold
<2-fold


E
DMSO
GDC-941

Supplementary Figure 1, Related to Figure 1. A) Representative images from formalin-fixed, paraffin-embedded prostate tissue, isolated from control (age-matched C57BL6/J or untreated transgenic animals) or 2, 6, or 12 months post tamoxifen administration to *Pten*$^{pce-/-}$/*Trp53*$^{pce-/-}$ or *Pten*$^{pce-/-}$/*Trp53*$^{pce-/-}$/*TMPRSS2-ERG*$^{pce+}$ animals. B) Quantification of F4/80 positive cells, or percent pixel positivity for Ly6G, Ki67, and α-SMA, in the tissue from A. n=2-5 age-matched control animals or n=13-16 tamoxifen-treated transgenic mice, pooled from two independent cohorts. Data shown as the mean ± SEM. Significance was determined by an unpaired t test with Welch's correction. C) Representative T2-weighted image by MRI of tumor-bearing *Pten*$^{pce-/-}$/*Trp53*$^{pce-/-}$/*TMPRSS2-ERG*$^{pce+}$ mice treated with vehicle or 0.6 mg Lupron subcutaneously every 28 days for two cycles, starting 4 months after tamoxifen administration. D) Percent of mice progressing on Lupron, as measured by doubling tumor volume post treatment (>2-fold) or below this threshold (<2-fold). n=3-5 mice per group, with significance determined by Fisher's exact test. E) PTE-24 cells were treated with 1 μM GDC-941 for 72 hrs and phase contrast images were acquired.